About Galectin Therapeutics
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: GALT
- Previous Close: $1.90
- 50 Day Moving Average: $1.22
- 200 Day Moving Average: $1.24
- 52-Week Range: $0.49 - $3.05
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.18
- P/E Growth: 0.00
- Market Cap: $55.85M
- Outstanding Shares: 29,396,000
- Beta: 2.12
- Return on Equity: -215.16%
- Return on Assets: -103.03%
Companies Related to Galectin Therapeutics:
- Current Ratio: 3.95%
- Quick Ratio: 3.95%
What is Galectin Therapeutics' stock symbol?
Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT."
Where is Galectin Therapeutics' stock going? Where will Galectin Therapeutics' stock price be in 2017?
3 brokerages have issued 12-month price objectives for Galectin Therapeutics' stock. Their forecasts range from $0.75 to $2.00. On average, they anticipate Galectin Therapeutics' share price to reach $1.42 in the next twelve months.
When will Galectin Therapeutics announce their earnings?
Galectin Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.
What are analysts saying about Galectin Therapeutics stock?
Here are some recent quotes from research analysts about Galectin Therapeutics stock:
According to Zacks Investment Research, "Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function. Galectin Therapeutics uses naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Galectin Therapeutics, formerly known as Pro-Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts. " (1/16/2017)
HC Wainwright analysts commented, "Be All, End All" (9/29/2016)
Who owns Galectin Therapeutics stock?
Galectin Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Richard E Uihlein (7.89%). Company insiders that own Galectin Therapeutics stock include Arthur Greenberg, James C Czirr, Kevin D Freeman and Peter G Traber.
How do I buy Galectin Therapeutics stock?
Shares of Galectin Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Galectin Therapeutics stock cost?
One share of Galectin Therapeutics stock can currently be purchased for approximately $1.90.